MaxCyte appoints Amanda Murphy as CFO

(Sharecast News) - Life sciences company MaxCyte named Amanda Murphy as its chief financial officer on Wednesday, succeeding long-time CFO Ron Holtz.
Prior to joining MaxCyte, Murphy specialised in gene therapy, gene editing and cell therapy equity research for both burgeoning private and established public healthcare companies - most recently as managing director of BTIG.

Holtz, who will remain on MaxCyte's board of directors, will retain certain elements of his former role - including overseeing accounting and budgeting/forecasting and supporting key business operations.

Chief executive Doug Doerfler said: "We are collectively witnessing the beginning of cell and gene therapies' impact on revolutionising medical treatment and saving human lives, and Amanda's wealth of experience - her deep understanding of the financial community and her unique, insightful, strategic view of the cell therapy sector - will support the continued development and expansion of MaxCyte's contribution in this space."

As of 0935 BST, MaxCyte shares were down 3.03% at 320.0p.